Pathophysiology, classification, and complications of common asymptomatic thrombocytosis in newborn infants [PDF]
Clinical and Experimental Pediatrics, 2022 We frequently encounter newborn infants with thrombocytosis in the neonatal intensive care unit. However, neonatal thrombocytosis is not yet fully understood.
Ga Won Jeon
doaj +1 more source
PREFERENTIAL NUCLEAR ACCUMULATION OF JAK2V617F IN CD34+ BUT NOT IN GRANULOCYTIC, MEGAKARYOCYTIC OR ERYTHROID CELLS OF PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA. [PDF]
, 2010 Recently, Dawson et al. identified a previously unrecognized nuclear role for JAK2 in the phosphorylation of the tyrosine 41 of the histone H3 with the exclusion of HP1a from chromatin and resulting in a disregulation of several JAK2-regulated genes such
Rinaldi, Ciro Roberto
core +2 more sources
Advances in management of pediatric chronic immune thrombocytopenia: a narrative review [PDF]
Journal of Yeungnam Medical Science, 2023 Immune thrombocytopenia (ITP) is a disease in which thrombocytopenia occurs because of immune-mediated platelet destruction and decreased platelet production.
Jae Min Lee
doaj +1 more source
Frontiers in Cell and Developmental Biology, 2022 C3G is a Rap1 guanine nucleotide exchange factor that controls platelet activation, aggregation, and the release of α-granule content. Transgenic expression of C3G in platelets produces a net proangiogenic secretome through the retention of ...
Luis Hernández-Cano +17 more
doaj +1 more source
Asian Journal of Transfusion Science, 2022 INTRODUCTION: Thrombopoietin (TPO) being the major regulator of megakaryopoiesis is expected to show a compensatory increase in immune thrombocytopenia (ITP), however, it is not so observed.
Gurleen Oberoi +5 more
doaj +1 more source
Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
EMBO Molecular Medicine, 2017 Congenital amegakaryocytic thrombocytopenia (CAMT) is an inherited disorder characterized at birth by thrombocytopenia with reduced megakaryocytes, which evolves into generalized bone marrow aplasia during childhood.
Alessandro Pecci +12 more
doaj +1 more source
The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN
Frontiers in Oncology, 2021 The myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis share driver mutations that either activate the thrombopoietin receptor, MPL, or indirectly activate it through mutations in the gene for JAK2, its ...
Jerry L. Spivak, Alison R. Moliterno
doaj +1 more source
The thrombopoietin receptor S264F mutant drives MPN with marrow fibrosis through a dual mechanism [PDF]
HemasphereHemaSphere, Volume 10, Issue 10, October 2026.
Lees C +9 more
europepmc +2 more sources
Thrombopoietin and platelet aggregation in patients with stable coronary artery disease
Platelets, 2017 Thrombopoietin (TPO) may facilitate platelet activation and aggregation. However, data on the impact of TPO on platelet aggregation in patients with stable coronary artery disease (CAD) are scarce.
Sanne Bøjet Larsen +5 more
doaj +1 more source
Turkish Journal of Hematology, 2015 Congenital amegakaryocytic thrombocytopenia (CAMT) generally begins at birth with severe thrombocytopenia and progresses to pancytopenia. It is caused by mutations in the thrombopoietin receptor gene, the myeloproliferative leukemia virus oncogene (c-MPL)
İkbal Ok Bozkaya +5 more
doaj +1 more source